Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 1 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 33 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Trim Therapeutics from Gent, company number BE1011963287, closed financial year 2025 with a result of € -2.9 million after tax. For that financial year Trim Therapeutics recorded a gross margin of € -627,329 and equity of € -2.8 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 27, 2026.
€ -2.8 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.9 million
Profit after tax over the fiscal year.
€ 1.4 million
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.9 million.
Debts at end 2025
€ 4.2 million
Loans from banks and other lenders, long and short.
€ 108,360
Supplier invoices still open on the last day of the fiscal year.
What happened to Trim Therapeutics?
What happened at Trim Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Katja Rosenkranz stepped down as director. NBB
- Bart Geers stepped down as director. NBB
- Willem Frans Broekaert stepped down as director. NBB
- Jérôme Laurent Van Biervliet stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2.9 million. Source: NBB ↗
- New establishment in Gent. KBO
- Katja Rosenkranz became a director. NBB
- Bart Geers became a director. NBB
Management
The stake of VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY, V-Bio Fund 2 comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Trim TherapeuticsThe shares are held by VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY (52.3%) and V-Bio Fund 2 (39.6%).
Directors
According to the 2025 annual accounts
Katja Rosenkranz
Director
since 2024 · until 2030
Bart Geers
Director
since 2024 · until 2030
Willem Frans Broekaert
Director
since 2024 · until 2030
since 2024 · until 2030
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Pieter van Reysschootlaan 2/104
9051 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1011.963.287
- VAT number
- BE 1011.963.287
- Registered office
- Pieter van Reysschootlaan 2/104, 9051 Gent
- Names & denominations
- Trim Therapeutics · Trim Tx
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 26 July 2024
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied